Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiac asthma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Cardiac asthma. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-011975-60 Sponsor Protocol Number: AC-060A202 Start Date*: 2010-09-30
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A multi-center, double-blind, placebo-controlled, parallel-group study to establish proof-of-concept and explore the efficacy of different doses of ACT-129968 in adult patients with partly contro...
    Medical condition: Allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-000774-23 Sponsor Protocol Number: CCD-0701-PR-0020 Start Date*: 2007-05-10
    Sponsor Name:Chiesi Farmaceutici S.p.A
    Full Title: EVALUATION OF CARDIAC SAFETY, TOLERABILITY AND EFFICACY OF CUMULATIVE DOSES OF CHF5188 pMDI (FIXED COMBINATION BUDESONIDE/CARMOTEROL 200/1 µg) COMPARED TO SAME CUMULATIVE DOSES OF CARMOTEROL pMDI A...
    Medical condition: Stable persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001791-11 Sponsor Protocol Number: KB003-04 Start Date*: 2012-08-09
    Sponsor Name:KaloBios Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects with Asthma Inadequately Controlled by Corticosteroids
    Medical condition: Asthma inadequately controlled by corticosteroids
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002139-34 Sponsor Protocol Number: Start Date*: 2008-08-01
    Sponsor Name:Imperial College London
    Full Title: The Pharmacokinetics of Inhaled Fluticasone Propionate delivered as Monodisperse Aerosols
    Medical condition: Healthy volunteers and mild to moderate asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052996 Inhalation therapy LLT
    9.1 10053349 Pharmacokinetic study LLT
    9.1 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022791-31 Sponsor Protocol Number: D01092010AZNTG Start Date*: Information not available in EudraCT
    Sponsor Name:University Erlangen-Nuremberg
    Full Title: Contrast sensitivity of patients with normal tension glaucoma by application of Azarga®
    Medical condition: The effect of AZARGA(R) on the central and spacial-temporal contrast sensitivity of patients with normal tension glaucoma will be examined. Healthy controls are required to prove the disease specif...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019279 Heart failure LLT
    12.1 10003555 Asthma bronchial LLT
    12.1 10021005 Hypoglycemia LLT
    12.1 10000456 Acid base balance LLT
    12.1 10054844 Anaphylactic reaction to drug LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004218-41 Sponsor Protocol Number: GB27862 Start Date*: 2012-06-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of LEBRIKIZUMAB in patients with uncontrolled asthma who are on inhaled corticosteroids and second ...
    Medical condition: Uncontrolled asthma despite the use of an inhaled corticosteroid and a second controller medication.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) SK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006013-24 Sponsor Protocol Number: OC000459/012/08 Start Date*: 2009-03-25
    Sponsor Name:Oxagen Ltd.
    Full Title: Dose Finding Study in Patients with Mild to Moderate Persistent Asthma: A Parallel Group, Randomised, Placebo Controlled, Double Blind Assessment of Oral OC000459 Dosed at Three Dose Schedules for ...
    Medical condition: Mild to moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019465-28 Sponsor Protocol Number: HZA113126 Start Date*: 2010-06-18
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on...
    Medical condition: subjects with mild asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002405-19 Sponsor Protocol Number: 204958 Start Date*: 2017-01-05
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open label, randomised, three arm, single dose, multicentre, parallel group study in healthy subjects to compare the pharmacokinetics of subcutaneous mepolizumab when delivered as a liquid drug ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016581-80 Sponsor Protocol Number: HZA113090 Start Date*: 2010-01-22
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020826-17 Sponsor Protocol Number: HZA113970 Start Date*: 2010-11-08
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label, non-randomized pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with severe renal impairment
    Medical condition: Healthy subjects vs subjects with asthma or COPD
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-003269-33 Sponsor Protocol Number: CD-RI-MEDI9929-1146 Start Date*: 2014-02-18
    Sponsor Name:MedImmune LLC(a wholly owned subsidiary of AstraZeneca PLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA )
    Full Title: A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) LT (Completed) LV (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-002699-42 Sponsor Protocol Number: DANBLOCK Start Date*: 2018-09-28
    Sponsor Name:Bispebjerg Frederiksberg Hospital
    Full Title: Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK)
    Medical condition: Myocardial infarction. We wish to test whether long-term treatment with betablocker (bisoprolol, carvedilol, metoprolol or nebivolol) leads to better prognosis than no treatment in patients sufferi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10028595 Myocardial infarct LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015499-88 Sponsor Protocol Number: KKSH-067 Start Date*: 2010-02-09
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg
    Full Title: Senkung einer erhöhten Herzfrequenz durch Ivabradin bei Patienten mit Multiorgandysfunktionssyndrom.
    Medical condition: Patienten mit MODS (Multiorgandysfunktionssyndrom)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003268-25 Sponsor Protocol Number: AT-03A-017 Start Date*: 2023-05-12
    Sponsor Name:Atea Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002225-10 Sponsor Protocol Number: EMPA-HEART Start Date*: 2016-09-28
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Impact of empagliflozin on left ventricular functions: a single center, phase III, randomized, open-label, active treatment-controlled, parallel study in patients with type 2 diabetes and normal le...
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002822-21 Sponsor Protocol Number: ARCHIE001 Start Date*: 2013-10-10
    Sponsor Name:University of Oxford
    Full Title: The early use of Antibiotics for at Risk CHildren with InfluEnza in primary care (ARCHIE): a double-blind randomised placebo-controlled trial
    Medical condition: Influenza or influenza-like illness
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020157-13 Sponsor Protocol Number: HZA111789 Start Date*: 2010-09-20
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label, non-randomized, pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with mild, moderate or severe he...
    Medical condition: healthy subjects and in subjects with mild, moderate or severe hepatic impairment
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052254 Hepatic impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005849-16 Sponsor Protocol Number: KIN001-203 Start Date*: 2021-03-09
    Sponsor Name:Kinarus AG
    Full Title: An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patient...
    Medical condition: COVID-19 development in hospitalized patients infected with SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023394-19 Sponsor Protocol Number: 9129 Start Date*: 2012-11-13
    Sponsor Name:Maatschap Cardiologie Isala
    Full Title: Early Beta blocker Administration before reperfusion in patients with ST-Elevation Myocardial Infarction who are planned to undergo primary PCI
    Medical condition: Patients with acute ST elevation myocardial infarction, scheduled for emergency coronary angioplasty
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10066641 Acute myocardial infarction, of anterior wall LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 25 17:09:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA